Duration of untreated illness as a predictor of treatment response and clinical course in generalized anxiety disorder

CNS Spectrums

Volumn 13, Issue 5, 2008, Pages 415-422

  Altamura, A Carlo ^a,b   Dell'Osso, Bernardo ^a   D'Urso, Nazario ^a   Russo, Michela ^c   Fumagalli, Sara ^c   Mundo, Emanuela ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; COMORBIDITY; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE COURSE; DISEASE DURATION; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 44849113507     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900016588     Document Type: Article

References (30)

1. Lieb R, Becker E, Altamura AC. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol. 2005;15:445-452.
2. Rynn MA, Brawman-Mintzer O. Generalized anxiety disorder: acute and chronic treatment. CNS Spectr. 2004;9:716-723.
3. Flint AJ. Generalized anxiety disorder in elderly patients: epidemiology, diagnosis and treatment options. Drugs Aging. 2005;22:101-114.
4. Ninan PT. Dissolving the burden of generalized anxiety disorder. J Clin Psychiatry. 2001;62(suppl 19):5-10.
5. Wittchen HU, Kessler RC, Beesdo K, Krause P, Hofler M, Hoyer J. Generalized anxiety and depression in primary care: prevalence, recognition and management. J Clin Psychiatry. 2002;63:24-34.
6. Kapczinski F, Lima MS, Souza JS, Schmitt R. Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev. 2003;CD003592.
7. Rickels K, Rynn M, Iyengar M, Duff D. Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. J Clin Psychiatry. 2006;67:41-47.
8. Stahl SM, Ahmed S, Haudiquet V. Analysis of the rate of improvement of specific psychic and somatic symptoms of general anxiety disorder during long-term treatment with venlafaxine ER. CNS Spectr. 2007;12:703-711.
9. Baldwin DS, Polkinghorn C. Evidence-based pharmacotherapy of generalized anxiety disorder. Int J Neuropsychopharmacol. 2005;8:293-302.
10. Guest JF, Russ J, Lenx-Smith A. Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalized anxiety disorder in the United Kingdom. Eur J Health Econ. 2005; January 29 [Epub ahead of print].
11. Kim TS, Pae CU, Yoon SJ, et al. Comparison of venlfaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder. Psychiatry Clin Neurosci. 2006;60:347-351.
12. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005;162:1785-1804.
13. Lieberman JA, Sheitman BB, Kinon BJ. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology. 1997;17:205-229.
14. Altamura AC, Bassetti R, Sassella F, Salvadori D, Mundo E. Duration of untreated psychosis as a predictor of outcome in first-episode schizophrenia: a retrospective study. Schizophr Res. 2001;52:29-36.
15. Goldberg JF, Ernst CL. Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder. J Clin Psychiatry. 2002;63:985-991.
16. Altamura AC, Dell'Osso B, Mundo E, Dell'Osso L. Duration of untreated illness in major depressive disorder: a naturalistic study. Int J Clin Pract. 2007;61:1697-1700.
17. Mundo. E, Santini, A, Salvadori, D, Altamura, AC. Duration of untreated illness (DUI) and clinical course in bipolar disorder. Paper presented at: Annual Meeting of the American Psychiatric Association; May 21-26. 2005; Atlanta, Ga.
18. Altamura AC, Dell'Osso B, Vismara S, Mundo E. May duration of untreated illness influence the long-term course of major depressive disorder? Eur Psychiatry. 2008;23:92-96.
19. Altamura AC, Santini A, Salvadori D, Mundo E. Duration of untreated illness in panic disorder: a poor outcome risk factor? Neuropsychiatr Dis Treat. 2005;1:1345-1347.
20. Pollack MH, Meoni R Otto MW, Simon N, Hackett D. Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short-and long-term studies. J Clin Psychopharmacol. 2003;23:250-259.
21. Diagnostic and Statistical Manual for Mental Disorders. 4th ed. text rev. Washington, DC: American Psychiatric Association; 2000
22. Allgulander C, Bandelow B, Hollander E, et al. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr. 2003;8:53-61.
23. First MB, Spitzer RL, Gibbon, et al. Structured Clinical Interview for DSM-IV Axis 1 (SCID-1), clinician version. Washington, DC: American Psychiatric Press; 1997.
24. Guy W, ECDEU Assessment Manual for Psychopharmacology. Publication ADM 76-338. Washington, DC: US Department of Health, Education and Welfare; 1976:218-222.
25. De Bellis MD, Casey BJ, Dahl RE, et al. A pilot study of amygdala volumes in pediatric generalized anxiety disorder. Biol Psychiatry. 2000;48:51-57.
26. De Bellis MD, Keshavan MS, Shifflett H, et al. Superior temporal gyrus volumes in pediatric generalized anxiety disorder. Biol Psychiatry. 2002;51:553-562.
27. Milham MP, Nugent AC, Drevets WC, et al. Selective reduction in amygdala volume in pediatric anxiety disorders: a voxel-based morphometry investigation. Biol Psychiatry. 2005;57:961-966.
28. Etkin A, Wager TD. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry. 2007;164:1476-1488.
29. Milad MR, Rauch SL. The role of the orbitofrontal cortex in anxiety disorders. Ann N Y Acad Sci. 2007;1121:546-561.
30. Sareen J, Jagdeo A, Cox BJ, et al. Perceived barriers to mental health service utilization in the United States, Ontario, and the Netherlands. Psychiatr Serv. 2007;58:357-364.